99 related articles for article (PubMed ID: 36930381)
1. Cytokine release syndrome was an independent risk factor associated with hypoalbuminemia for patients with relapsed/refractory hematological malignancies after CAR-T cell therapy.
Ding S; Chen R; Wang L; Zu C; Zhou X; Zhang J; Zhang M; Jin A; Wang T; Hu Y
BMC Cancer; 2023 Nov; 23(1):1055. PubMed ID: 37919691
[TBL] [Abstract][Full Text] [Related]
2. Cytokine Release Syndrome after Chimeric Antigen Receptor Transduced T-Cell Therapy in Cancers: A Systematic Review.
Taheri S
Saudi J Kidney Dis Transpl; 2022 Nov; 33(6):795-823. PubMed ID: 38018721
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T-Cell Therapy for Cancer and Heart: JACC Council Perspectives.
Ganatra S; Carver JR; Hayek SS; Ky B; Leja MJ; Lenihan DJ; Lenneman C; Mousavi N; Park JH; Perales MA; Ryan TD; Scherrer-Crosbie M; Steingart RM; Yang EH; Zaha V; Barac A; Liu JE
J Am Coll Cardiol; 2019 Dec; 74(25):3153-3163. PubMed ID: 31856973
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic use of interleukin 6 monoclonal antibody can reduce CRS response of CAR-T cell therapy.
Dou B; Ren S; Qiu L; Zhang X; Zhang N; Cai J; Chen D; Zhang Q; Yao H; Fan F
Front Med (Lausanne); 2023; 10():1265835. PubMed ID: 38264058
[TBL] [Abstract][Full Text] [Related]
5. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy.
Gutierrez C; Neilan TG; Grover NS
Blood; 2023 May; 141(20):2452-2459. PubMed ID: 36827628
[TBL] [Abstract][Full Text] [Related]
6. Communication from the ISTH SSC Subcommittee on Hemostasis and Malignancy: a meta-analysis to assess the risk of bleeding and thrombosis following chimeric antigen receptor T-cell therapy.
Bindal P; Patell R; Chiasakul T; Lauw MN; Ko A; Wang TF; Zwicker JI
J Thromb Haemost; 2024 Apr; ():. PubMed ID: 38574863
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular toxicity of immune therapies for cancer.
Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
[TBL] [Abstract][Full Text] [Related]
8. Infections in haematology patients treated with CAR-T therapies: A systematic review and meta-analysis.
Reynolds GK; Sim B; Spelman T; Thomas A; Longhitano A; Anderson MA; Thursky K; Slavin M; Teh BW
Crit Rev Oncol Hematol; 2023 Dec; 192():104134. PubMed ID: 37739146
[TBL] [Abstract][Full Text] [Related]
9. FDG-PET in Chimeric Antigen Receptor T-Cell (CAR T-Cell) Therapy Toxicity: A Systematic Review.
Al-Ibraheem A; Abdlkadir AS; Lopci E; Allouzi S; Paez D; Alkuwari M; Makoseh M; Novruzov F; Usmani S; Al-Rabi K; Mansour A
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730680
[TBL] [Abstract][Full Text] [Related]
10. Cognition following chimeric antigen receptor T-cell therapy: A systematic review.
Kazzi C; Kuznetsova V; Siriratnam P; Griffith S; Wong S; Tam CS; Alpitsis R; Spencer A; O'Brien TJ; Malpas CB; Monif M
J Autoimmun; 2023 Nov; 140():103126. PubMed ID: 37837807
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular Complications of Novel Anti-Cancer Immunotherapy: Old Problems from New Agents?
Chung WB; Youn JC; Youn HJ
Korean Circ J; 2020 Sep; 50(9):743-753. PubMed ID: 32725983
[TBL] [Abstract][Full Text] [Related]
12. Cytokines Are at the Heart of It: Cytokine Release Syndrome Underlies Cardiovascular Effects of CAR T Cell.
Catino AB
JACC CardioOncol; 2020 Jun; 2(2):204-206. PubMed ID: 34396229
[TBL] [Abstract][Full Text] [Related]
13. Guarding the Heart in an Era of "Tachy-CAR-T": The Rapid Proliferation of a Transformative Therapy.
Blue B; Alomar M; Locke FL
JACC CardioOncol; 2023 Dec; 5(6):755-757. PubMed ID: 38204996
[TBL] [Abstract][Full Text] [Related]
14. Impact of Cytokine Release Syndrome on Cardiac Function After Chimeric Antigen Receptor-T Cell Therapy.
Sunayama I; Min KD; Orihara Y; Oboshi M; Yoshihara S; Yoshihara K; Tamaki H; Teramoto M; Nishimura K; Eguchi A; Naito Y; Higasa S; Asakura M; Ishihara M
JACC Asia; 2023 Dec; 3(6):944-946. PubMed ID: 38155799
[No Abstract] [Full Text] [Related]
15. Preliminary assessment of cardiotoxicity in chimeric antigen receptor T cell therapy: a systematic review and meta-analysis.
Guo M; Wang X; Xiao S; Liu A; Xu T; Huan C; Wu H; Hu Y; Zhou S; Zhu H; Pan D
Clin Exp Med; 2023 Oct; 23(6):2041-2050. PubMed ID: 36930381
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular Toxicities with Chimeric Antigen Receptor T-cell Therapy.
Gill J
Curr Cardiol Rev; 2023; 19(1):e230622206353. PubMed ID: 35747980
[TBL] [Abstract][Full Text] [Related]
17. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment.
Nenna A; Carpenito M; Chello C; Nappi P; Annibali O; Vincenzi B; Grigioni F; Chello M; Nappi F
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897819
[TBL] [Abstract][Full Text] [Related]
18. Imaging-based Toxicity and Response Pattern Assessment Following CAR T-Cell Therapy.
Smith DA; Kikano E; Tirumani SH; de Lima M; Caimi P; Ramaiya NH
Radiology; 2022 Feb; 302(2):438-445. PubMed ID: 34751616
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
